Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD
Diana V. Do, MD
Peter K. Kaiser, MD
Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
Arshad M. Khanani, MD, MA
Karl Csaky, MD, PhD
Christina Y. Weng, MD, MBA, FASRS
Making the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying
Carl Regillo, MD
Jennifer I. Lim, MD, FARVO
GET REAL: A Guide to Evolving Treatment of nAMD and DME Using Real-World Data
Theodore Leng, MD, MS
Extending Treatment Durability With Next-Generation Neovascular AMD Therapies
Durga Borkar, MD, MMCi
Improving Outcomes in Patients with RVO: Tailoring Treatment
Carl Danzig, MD
Taking the Patient-Centered Approach to Mycophenolate Risk Mitigation
Cara Dolin, MD
Jennifer Simpson
Diana Girnita, MD ,PhD
A Closer Look at Real-World Strategies for Treatment-Resistant DME
Reducing Retina Treatment Burden in the Real World: Emerging Evidence with Treatment Advances
Jayanth Sridhar, MD
Sabin Dang, MD
Real-World Treatment of Retinal Disease
Real-World Outcomes with Durable Treatments for Retinal Diseases
Reconsidering the Algorithm: DME
Reconsidering the Algorithm: nAMD
A Look at the Numbers: Cost of Durable Treatments in Retinal Disease
Reconsidering the Algorithm: Treatment-Resistant DME
Clinical Evidence for Durable Treatment of nAMD
Loading...
We’re glad to see you’re enjoying Eye Health Academy… but how about a more personalized experience?
Press cancel to remain on Eye Health Academy. Press the link below or the continue button to keep going.